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ABSTRACT
Epstein-Barr virus (EBV) expresses few viral proteins in nasopharyngeal carcinoma (NPC) but high levels of BamHI-A rightward tran-
scripts (BARTs), which include long noncodingRNAs (lncRNAs) andBARTmicroRNAs (miRNAs). It is hypothesized that themecha-
nism for regulation of BARTsmay relate to EBVpathogenesis inNPC.We showed that nuclear factor-B (NF-B) activates the BART
promoters andmodulates the expression of BARTs in EBV-infectedNPC cells but that introduction ofmutations into the putative
NF-Bbinding sites abolished activation of BARTpromoters byNF-B. Binding of p50 subunits toNF-B sites in theBARTpromot-
ers was confirmed in electrophoreticmobility shift assays (EMSA) and further demonstrated in vivo using chromatin immunoprecipi-
tation (ChIP) analysis. Expression of BARTmiRNAs and lncRNAs correlatedwithNF-Bactivity in EBV-infected epithelial cells, while
treatment of EBV-harboringNPCC666-1 cells with aspirin (acetylsalicylic acid [ASA]) and the IBkinase inhibitor PS-1145 inhibited
NF-Bactivity, resulting in downregulation of BART expression. Expression of EBVLMP1 activates BARTpromoters, whereas an
LMP1mutantwhich cannot induceNF-Bactivation does not activate BARTpromoters, further supporting the idea that expression
of BARTs is regulated byNF-B signaling. Expression of LMP1 is tightly regulated inNPC cells, and this study confirmed thatmiR-
BART5-5p downregulates LMP1 expression, suggesting a feedback loop betweenBARTmiRNAandLMP1-mediatedNF-Bactivation
in theNPC setting. These findings provide new insights into themechanismunderlying the deregulation of BARTs inNPCand identify
a regulatory loop throughwhichBARTs support EBV latency inNPC.
IMPORTANCE
Nasopharyngeal carcinoma (NPC) cells are ubiquitously infectedwith Epstein-Barr virus (EBV).Notably, EBV expresses very few viral
proteins inNPC cells, presumably to avoid triggering an immune response, but high levels of EBVBARTmiRNAs and lncRNAswhich
exhibit complex functions associatedwith EBVpathogenesis. Themechanism for regulation of BARTs is critical for understanding
NPConcogenesis. This study providesmultiple lines of evidence to show that expression of BARTs is subject to regulation byNF-B
signaling. EBVLMP1 is a potent activator ofNF-B signaling, andwe demonstrate that LMP1 canupregulate expression of BARTs
throughNF-B signaling and that BARTmiRNAs are also able to downregulate LMP1 expression. It appears that aberrantNF-B sig-
naling and expression of BARTs forman autoregulatory loop formaintaining EBV latency inNPC cells. Further exploration of how
targetingNF-B signaling interrupts EBV latency inNPC cellsmay reveal newoptions forNPC treatment.
Epstein-Barr virus (EBV) is a common human herpesviruswhich infects more than 95% of adults worldwide (1). Besides
causing lifelong persistent latent infections in humans, EBV is
associated with several malignancies, including Burkitt’s lym-
phoma (2), Hodgkin’s disease (3), nasal NK/T cell lymphoma (4,
5), and epithelial tumors like nasopharyngeal carcinoma (NPC)
and gastric carcinoma (GC) (6, 7). EBV is one of the few human
viruses which can undergo true latency in which viral gene expres-
sion is stringently restricted, except for that of a few essential viral
antigens, and which produces virtually no detectable viral parti-
cles in vivo (8). Based on the spectrum of viral gene expression,
different latency forms, designated 0, I, II, and III, have been char-
acterized in EBV infection and in EBV-associated tumors (9).
While most EBV latent antigens are expressed only in the latency
III form seen in EBV-associated posttransplant lymphoprolifera-
tive diseases, it is notable that in all forms of latency, EBV ex-
presses small noncoding RNAs (EBERs) and a family of BamHI-A
rightward transcripts (BARTs). EBERs have been widely used in
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pathological diagnosis of NPC and are suggested to interfere with
host interferon expression through interaction with the PKR
pathway (10, 11). The role of BARTs in EBV-infected cells has
remained mostly unknown until recent years. BARTs were first
identified as large multispliced transcripts in NPC tissues and were
later found to be expressed in EBV-infected cells and EBV-associ-
ated tumors (12–16). In addition to the family of BART mRNAs
which are produced by alternative splicing (17), there are two
clusters of microRNAs (miRNAs) generated from introns of
BARTs (18). However, attempts to identify protein expression
from putative open reading frames in BART mRNAs have failed
to generate any convincing findings (19). Nevertheless, BART
miRNAs have been revealed to possess diverse functions, and
BART mRNAs are likely to be functional long noncoding RNAs
(lncRNAs) (20–23). Similar to EBNA1, which is essential for EBV
latent replication, BARTs are consistently expressed at high levels
in NPC (13, 14). BART expression is suggested to be deregulated
in EBV-associated malignancies (24). We previously reported that
BARTs are expressed from two promoters, P1 and P2, with the P1
promoter as the predominant initiation site (25, 26). Several po-
tential binding sites for transcription factors such as CCAAT/en-
hancer binding protein (C/EBP), c-Myc, SP1, AP1, and interferon
regulatory factor (IRF) have been identified around the P1 and P2
promoters. C/EBP and c-Myc were found to positively regulate P2
activity, and IRF-5 and -7 appear to regulate P1 activity (25). An-
other study showed that in EBV-infected B cell lines, methylation
may play a role in regulating expression from BART promoters
(27). It is not yet known how BART promoters are regulated to
maintain the high-level expression of BARTs seen in NPC.
It is postulated that aberrant cellular signaling and viral func-
tions may jointly contribute to regulate and maintain BART ex-
pression in EBV-associated tumors. In NPC cells, constitutive ab-
errant activation of STAT3 and nuclear factor-B (NF-B) has
been described (28–30). The latent membrane protein 1 (LMP1)
gene is a major EBV oncogene, and LMP1 functions as a consti-
tutively active tumor necrosis factor (TNF) receptor, capable of
activating several signaling pathways, including the NF-B path-
way (31). LMP1 signaling is important to the survival of latently
infected cells because it upregulates antiapoptotic proteins and
provides growth signals (32). LMP1 is also reported to upregulate
its own expression through the NF-B signaling pathway (33). It is
intriguing that levels of LMP1 expression in NPC cells were found
to be variable and even undetectable in some cases. Because LMP1
is able to activate several signaling pathways which strongly pro-
voke the host immune response, it is possible that NPC cells adopt
a mechanism to modulate the level of LMP1 expression in order to
evade host immune surveillance. Interestingly, several BART
miRNAs have been reported to downregulate LMP1; this may
control LMP1 expression in EBV-infected tumor cells (34, 35).
We found putative NF-B regulatory motifs located in the
BART promoter region in addition to the previously characterized
C/EBP and c-Myc regulatory elements. Since activated NF-B is con-
stitutively present in NPC cells, it seems possible that aberrantly acti-
vated NF-B may play a role in upregulating expression of BARTs in
these cells. To verify this hypothesis, we provide evidence showing
that the BART promoters respond positively to NF-B activation and
that LMP1 can upregulate BART expression through the NF-B
pathway. In addition, BART expression can be downregulated by
treatment with inhibitors which block NF-B signaling. We further
confirmed that BART miRNAs downregulate LMP1 expression
through targeting of the 3= untranslated region (UTR). A mechanism
is proposed in which LMP1 and BART miRNA expression forms an
autoregulatory loop through NF-B signaling in NPC cells; this
mechanism is likely to contribute to EBV latency and to the establish-
ment and progress of NPC malignancy.
MATERIALS AND METHODS
Cell lines and cell culture conditions. Human embryonic kidney (HEK)
293T cells, NPC CNE2, HeLa-Bx1, and HEK 293T virus-packaging Phoe-
nix cells were maintained in Dulbecco’s minimal essential medium
(Gibco) supplemented with 10% fetal bovine serum (FBS) and 1% peni-
cillin-streptomycin (P-S). The EBV-positive NPC cell line C666-1 was
grown in RPMI 1640 medium (Gibco) supplemented with 10% FBS and
1% P-S, and the EBV-positive GC cell line AGS-Bx1 was cultured in F-12K
nutrient mixture (Gibco) supplemented with 10% FBS and 1% P-S.
C666-1 cells were treated for 48 h with 4 mM aspirin (acetylsalicylic acid
[ASA]; Sigma) or 0.2 mM PS-1145 dihydrochloride (Santa Cruz) to in-
hibit NF-B activity. All cells were cultured at 37°C with 5% CO2.
Plasmids. BART promoter reporter plasmids were constructed by clon-
ing the inserts from the previously described BART P1 and P2 promoter
plasmids (25) into the pGL2 (Amersham Pharmacia) luciferase reporter plas-
mid. The LMP1 expression vector was constructed by cloning the coding
region of LMP1 into a V5-tagged pSG5 vector. The pcDNA3.1-EGFP (where
EGFP is enhanced green fluorescent protein) expression vectors containing
NF-B p50 and p65 and the IB expression plasmid containing the
IB-AA mutation and NF-B-responsive reporter were kindly provided by
Zhenguo Wu (Hong Kong University of Science and Technology, Hong
Kong, People’s Republic of China) (36). NF-B p65 was also subcloned into
a 5= Flag-tagged pcDNA3.1 vector in this study. For the construction of cell
lines stably expressing LMP1, we cloned the LMP1 gene including its 3= un-
translated region (3= UTR) (GenBank accession number V01555.2; nucleo-
tides 167120 to 169474) into the pBABE-Puro vector (Cell Biolabs, Inc.).
Full-length and truncated forms of the 3= UTR of LMP1 (GenBank accession
number V01555.2; nucleotides 167120 to 168159) were cloned into the clon-
ing site downstream of firefly luciferase in a pmirGLO Dual-Luciferase
miRNA Target Expression Vector (Promega). Mutagenesis of the BART pro-
moter and LMP1 was performed using a QuikChange site-directed mutagen-
esis kit (Stratagene), as described by the manufacturer. Primers are listed in
Table 1.
EMSA. Nuclear extracts for electrophoretic mobility shift assay
(EMSA) were prepared from HEK 293T cells transfected with pcDNA3.1-
EGFP-p50 and pcDNA3.1-Flag-p65. Cells were lysed using a sucrose buf-
fer containing 0.5% NP-40, and the nuclei were washed and then resus-
pended in a hypotonic buffer. The nucleoplasm was extracted using a
hypertonic buffer, and nuclear extracts were stored at 80°C following
protein quantification. EMSA 5= IRDye 700-labeled oligonucleotides were
purchased from Integrated DNA Technologies and annealed to obtain
double-stranded DNA probes. Binding reactions were performed as de-
scribed by the manufacturer, and gels were visualized using an Odyssey
infrared EMSA kit (Li-Cor Biosciences). Supershift experiments were per-
formed with 2g of rabbit anti-p50 (sc-7178; Santa Cruz), rabbit anti-p65
(sc-7151; Santa Cruz), or rabbit control IgG (ab46540; Abcam).
ChIP assay. Briefly, HEK 293T cells were transfected with the BART
promoter plasmid BART P1, pcDNA3.1-EGFP-p50, and pcDNA3.1-
FLAG-p65 and were harvested after 48 h. The chromatin immunoprecipi-
tation (ChIP) extract was sonicated into between 100- and 750-bp DNA
fragments using a Sonicator S-4000 (Misonix). For immunoprecipitation,
5 l of rabbit anti-GFP (A6455; Invitrogen), 5 g of rabbit anti-Flag
(F7425; Sigma) or 5g of rabbit control IgG (ab46540; Abcam) was used,
and antibody-protein-DNA complexes were pulled down using Dyna-
beads protein A (Invitrogen). The level of immunoprecipitated DNA was
determined by real-time PCR using a primer pair that amplified the BART
P1 promoter region, including the putative NF-B site, and a primer pair
covering a genomic region about 5 kb upstream of the interleukin-8 (IL-8)
promoter that served as a negative control (Table 1).
Verhoeven et al.
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Luciferase reporter assay. HEK 293T cells were seeded at a density of
approximately 70% in 24-well and 48-well plates a day before transfection
and subsequently transfected using TransIT-LT1 transfection reagent
(Mirus) or Lipofectamine 2000 (Invitrogen). For data normalization pur-
poses, the plasmid phRL-TK (Promega) expressing Renilla luciferase was
cotransfected with the firefly reporter plasmid in each experiment. For
miRNA reporter assays, 25 ng of pmirGLO, with or without an insert, was
cotransfected with 50 nM RNA duplexes.
Immunoblotting. Membranes were incubated overnight with pri-
mary antibodies at a dilution of 1:1,000. The antibodies used for immu-
noblotting include rabbit anti-NF-B p50 (sc-7178; Santa Cruz), rabbit
anti-NF-B p65 (sc-7151; Santa Cruz), rabbit anti-Bcl-3 (sc-185; Santa
Cruz), mouse anti--tubulin (sc-55529; Santa-Cruz), rabbit anti-IB
(9242S; Cell Signaling), mouse anti-phospho-IB (5A5; Cell Signaling),
mouse anti-lamin AC (ab8984; Abcam), and mouse anti-LMP1
(OT21C; kindly provided by Jaap Middeldorp, VU University, Amster-
dam, The Netherlands). Membranes were then incubated with IRDye
700-labeled donkey anti-mouse or anti-rabbit or IRDye 800-labeled don-
key anti-mouse (Li-Cor Biosciences) at a 1:5,000 dilution. Blots were de-
tected using an Odyssey infrared imaging system.
Construction of stable cell lines expressing LMP1. Virus-packaging
HEK 293T Phoenix cells were transfected with a pBABE-LMP1-3= UTR or
pBABE-empty vector. Infected cells were selected by culturing in medium
supplemented with 2.5 g/ml puromycin.
RT and real-time PCR amplification. RNA was extracted from cells
using RNAiso Plus reagent (TaKaRa) and reverse transcribed with gene-
specific reverse transcription (RT) primers or random primers using a
high-capacity cDNA reverse transcription kit (Applied Biosystems). The
real-time PCR was performed using SYBR Premix Ex Taq (Tli RNase H
Plus) mix (TaKaRa) in a LightCycler 480 instrument (Roche). Primers
used to amplify the alternatively spliced BART RNAs, BARF0, RPMS1,
RPMS1A, and A73, are listed in Table 1, and gene expression was normal-
ized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The real-time PCR amplification was performed with miRNA-specific
TaqMan probes using SensiFAST Probe Lo-ROX mix (Bioline) in a Light-
Cycler 480 instrument. Primers and probes used for BART miRNA detec-
tion were described previously (37). To determine EBV copy number, a
75-bp fragment of the BamH-W region (GenBank accession number
V01555.2; nucleotides 17721 to 17796) was amplified by quantitative PCR
(qPCR) from phenol-chloroform-extracted DNA. The same fragment
was cloned into the TA cloning vector pMD18-T, which was then serially
diluted to obtain a standard curve.
Multiplex reverse transcription and real-time PCR amplification of
BART miRNAs. All of the miRNA sequences used in this study were
obtained from the Sanger Institute database (miRBase). RNA was re-
verse transcribed in a mix containing two specific stem-loop primers
using a TaqMan microRNA reverse transcription kit (Applied Biosys-
tems). Real-time PCRs were performed with miRNA-specific TaqMan
probes using SensiFAST Probe Lo-ROX mix in a LightCycler 480 in-
strument. Primers and probes used for BART miRNA detection have
been described previously (37).
TABLE 1 Oligonucleotides used in this study
Oligonucleotide Sequence (5=–3=)a
pBABE-LMP13=UTR-BamHI-S CGCGGATCCATGGAACACGACCTTGAGAG
pBABE-LMP13=UTR-EcoRI-AS CCGGAATTCCTCCTCCCAACGCGTTTCTG
pmiRGLO-LMP1-XbaI-S CTAGTCTAGACCTTTCTTTACTTCTAGGCA
pmiRGLO-LMP1-SalI-AS ACGCGTCGACCTCCTCCCAACGCGTTTCTG
pmiRGLO-LMP1-168099-XbaI-S CTAGTCTAGAGACTGACTCTCCCTCCAT
pmiRGLO-LMP1-168051-XbaI-S CTAGTCTAGAACTGGCACACACTCCCTT
LMP1-Y384ID-S GCCCAGTTCAGCTAAGCATC---GACTAAGGATCCAGATC
LMP1-Y384ID-AS GATCTGGATCCTTAGTC---GATGCTTAGCTGAACTGGGC
ChIP-BART-S CCTGCTTCTCAGGCCTAAAT
ChIP-BART-AS CAGCTTGAAAAATGGCAACC
ChIP-IL8up-S TCCCTAAGTCACTTTCTTCAAGTTGC
ChIP-IL8up-AS CGTGCATTTAATTGTGTCTTGTGG
miR-control-top 5Phos/rCrUrArGrUrArUrGrArCrUrArGrUrArUrGrArUrCrCrGrG
miR-control-bottom rGrGrArUrCrArUrArCrUrArGrUrCrArUrArCrUrArGrArC
miR-BART3-3p-top 5Phos/rCrGrCrArCrCrArCrUrArGrUrCrArCrCrArGrGrUrGrU
miR-BART3-3p-bottom rArCrCrUrGrGrUrGrArCrUrArGrUrGrGrUrGrCrGrCrU
miR-BART5-5p-top 5Phos/rCrArArGrGrUrGrArArUrArUrArGrCrUrGrCrCrCrArUrGrC
miR-BART5-5p-bottom rArUrGrGrGrCrArGrCrUrArUrArUrUrCrArCrCrUrUrGrArG
miR-BART7-3p-top 5Phos/rCrArUrCrArUrArGrUrCrCrArGrUrGrUrCrCrArGrGrG
miR-BART7-3p-bottom rCrUrGrGrArCrArCrUrGrGrArCrUrArUrGrArUrGrCrA
miR-BART13-3p-top 5Phos/rUrGrUrArArCrUrUrGrCrCrArGrGrGrArCrGrGrCrUrGrA
miR-BART13-3p-bottom rArGrCrCrGrUrCrCrCrUrGrGrCrArArGrUrUrArCrArGrA
miR-BART14-3p-top 5Phos/rUrArArArUrGrCrUrGrCrArGrUrArGrUrArGrGrGrArU
miR-BART14-3p-bottom rCrCrCrUrArCrUrArCrUrGrCrArGrCrArUrUrUrArCrA
F-V(A/B) (BARF0/RPMS1A) TCTTCTAGAGGACGCAGGATATCTGCAGGATCAGAGG
F-V (RPMS1/A73) GAAAAGCTTGGGATTAATGCCTGGACCCTCACCAG
R-VII(D) (RPMS1/RPMS1A) AGGGGATCCCCCGCCACCACGGTGCAGCCTAC
R-VII(A/B) (BARF0/A73) AGGGGATCCGCACCCCCAGTACCGGGCCATCCG
F-GAPDH GAAGGTGAAGGTCGGAGTA
R-GAPDH GAAGATGGTGATGGGATTTC
F-EBV-BamH-W CCCAACACTCCACCACACC
R-EBV-BamH-W TCTTAGGAGCTGTCCGAGGG
EBV-BamH-W probe (6 FAM)CACACACTACACACACCCACCCGTCTC(TAM)
a Underlining indicates altered nucleotides, hyphens indicate deleted nucleotides, 5Phos indicates a 5= phosphate end, and r indicates RNA. 6 FAM is 6-carboxyfluorescein, and
TAM is 6-carboxytetramethylrhodamine.
Regulation of EBV BARTs in NPC
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Statistics. The statistical analysis in this study was performed using
GraphPad Prism, version 5, software. Significance values (P values) were
calculated using a two-tailed Student’s t test.
RESULTS
NF-B positively regulates BART promoters. We previously
identified two promoters which drive expression of BARTs and
characterized host factors which regulate the activity of these pro-
moters. Further examination of BART promoter sequences re-
vealed that there are several potential binding sites for NF-B (Fig.
1A). To test if these motifs mediate activation of BART promoters
via NF-B, we constructed reporters which contained either the
BART P1 or BART P2 region and the corresponding NF-B sites
(Fig. 1B). Mutations introduced into different combinations of
binding sites caused various degrees of attenuation of activation of
the BART promoters by NF-B; activation of BART promoter
activity was almost completely abolished when all sites were mu-
tated (Fig. 1C). The effect of NF-B p50 and p65 subunits on the
BART P1 and P2 promoters was examined in HEK 293T cells in a
transfection experiment. Overexpression of p50 and p65 resulted
in an excess of dimers relative to the level of cellular IB inhibitors,
resulting in more free and active dimers (33). Results obtained
here confirm our previous findings that C/EBP and c-Myc act as
positive regulators for BART expression (25). NF-B p50 and p65
were cotransfected individually or together into HEK 293T cells
with either a BART P1 or P2 reporter plasmid to further charac-
terize their roles in BART promoter activation. Both p50 and p65
activated the P1 and P2 promoters. Notably, overexpression of
p50 and p65 together strongly activated the BART reporters to a
greater extent than expression of either C/EBP or c-Myc (Fig. 1D
and E). These results indicate that BART promoters contain
NF-B binding sites and that NF-B signaling is a dominant reg-
ulator for BART promoter activity in cells.
NF-B p50 binds the BART promoters in vitro and in vivo.
We further tested if the p50 and p65 NF-B subunits are able to
bind to the BART promoters. An electrophoresis mobility shift
assay (EMSA) was performed using IRDye 700-labeled probes
covering the BART P1 (BART P173/54) and BART P2 (BART
P217/2) NF-B sites and nuclear extract prepared from HEK
293T cells transfected with GFP-tagged p50 and FLAG-tagged p65
expression plasmids (Fig. 2A). Protein-DNA complexes could be
detected with nuclear extracts prepared from cells transfected with
p50 and p65 (Fig. 2B and C, lanes 3) but not with nuclear extracts
from untransfected cells. Unlabeled wild-type (WT) probes
showed higher competitive ability than probes containing muta-
tions in the NF-B site (lanes 4 and 5), suggesting that NF-B
subunit binding is associated with the putative NF-B motifs. The
inability of excess unlabeled probe to completely outcompete la-
beled probe may be due to high affinity of p50/p65 for the NF-B
sites, but this idea needs to be further evaluated with other NF-B
sites. To further verify the specificity of the shifted protein-DNA
complex, supershift assays with antibodies to either p50 or p65
were performed. The complex was supershifted with a p50 anti-
body (Fig. 2B, lane 8), confirming the presence of p50 in the com-
plex. However, the p65 antibody failed to shift the complex, which
could be due to the putative NF-B site consisting of only a p50
half-site, possibly preventing p65 antibody binding to the com-
plex (Fig. 2B and C, lanes 9). It is also possible that the anti-p65
antibody chosen is not suitable for use in the supershift assay as the
BART P2 complex is also supershifted by anti-p50 but not by
anti-p65 (Fig. 2C, lanes 8 and 9). Rabbit control IgG antibody did
not result in any supershifted complexes, supporting the specific-
ity of the supershift reactions (Fig. 2B and C, lanes 10). The ab-
sence of a supershift with the p65 antibody in the EMSA with both
BART P1 and P2 probes may suggest that p50 is a key subunit for
NF-B binding to BART promoters.
To further verify the role of NF-B signaling in regulation of
EBV BART promoters, a chromatin immunoprecipitation
(ChIP) assay was performed to explore the ability of p50 and
p65 to bind the putative NF-B binding sites in the BART
promoters in vivo. GFP-tagged p50 and Flag-tagged p65 were
cotransfected with the P1 reporter into HEK 293T cells, and cell
lysates were precipitated with either anti-GFP, anti-Flag, or
control IgG. The p50 (via anti-GFP)-enriched BART promoter
DNA in the precipitates appeared to be almost 80-fold more
abundant than that precipitated by rabbit control IgG, while
for p65 (via anti-Flag), a moderate enrichment of approxi-
mately 20-fold over the control antibody was observed (Fig.
2D). The lower enrichment for p65 than that for p50 in the
ChIP experiment supports the suggestion that p50 dictates the
interaction with BART promoter NF-B motifs. These results
suggest that NF-B p50 and, to a lesser extent, p65 are able to
bind to the BART promoters in vitro and in vivo.
LMP1 activates BART promoters through NF-B signaling.
Since LMP1 is a known activator of NF-B signaling, we tested if
LMP1 can activate the BART promoters through this pathway.
For this purpose we first made an LMP1 mutant (LMP1-IDmut)
with impaired NF-B activation ability by mutating the YYD
amino acid sequence in C-terminal activating region 2 (CTAR2)
of LMP1 to ID (Fig. 3A) (38). The impaired ability of LMP1-
IDmut to induce NF-B activation was confirmed using an
NF-B reporter (Fig. 3B). Immunoblot analysis using LMP1-spe-
cific antibodies confirmed expression of the LMP1 mutant in
transfected cells (Fig. 3B, bottom panel). Reporter assays with the
BART promoters showed that LMP1 could activate both BART P2
and P1 approximately 4-fold more strongly than the control in
HEK 293T cells (Fig. 3C). Cotransfection of LMP1 with IB-AA,
an IBmutant which cannot be phosphorylated, abolished acti-
vation of BART promoters by LMP1, confirming that the positive
effect on BART promoters is mediated by NF-B signaling. The
role of NF-B signaling in LMP1 activation of BART promoters
was further confirmed using LMP1-IDmut, which showed atten-
uated ability to activate BART promoters (Fig. 3C). Activation of
BART promoters by LMP1 through NF-B signaling also oc-
curred in NPC CNE2 cells, with upregulation also being dimin-
ished with LMP1-IDmut or coexpression of LMP1 with IB-AA
(Fig. 3D). Taken together, these results show that LMP1 can acti-
vate the BART promoters, largely through NF-B signaling.
To further confirm regulation of BART expression by LMP1,
we stably expressed LMP1 in the EBV-infected epithelial cell lines
AGS-Bx1, HeLa-Bx1, and NPC C666-1 and then compared the
expression levels of BART miRNAs and lncRNAs. LMP1 expres-
sion was confirmed in these cell lines compared to expression in
vector control cell lines (Fig. 4A). Overexpression of LMP1 in
AGS-Bx1 and HeLa-Bx1 cells stably expressing LMP1 resulted
in significant upregulation of BART lncRNAs. Examination of
miRNA expression profiles revealed that most BART miRNAs
were upregulated to various degrees, with the only exception be-
ing miR-BART3-3p (Fig. 4B and C). Expression of BARTs com-
prises both BART miRNAs and BART lncRNAs. Examination of
Verhoeven et al.
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FIG 1 NF-B activates EBV BART promoters. (A) Sequence of the BART promoter region showing the locations of previously identified transcription factor
binding sites (underlined), putative NF-B binding sites (bold and underlined, with p65 and p50 sites within the region included in the BART P1 reporter shown
in red and blue, respectively), and P1 and P2 RNA initiation sites (arrows). The nucleotide coordinates, 150150 to 150709, are based on the EBV B95-8 genome.
(B) Illustration of P1 and P2 reporter constructs (solid black). (C) Location of mutations introduced into the P1 reporter at putative NF-B p50 (blue) and p65
(red) half-sites. HEK 293T cells were cotransfected with p50 and p65 expression vectors together with the BART P1 promoter reporter with and without
mutations. Relative luciferase activity is expressed as the fold change compared to the level of wild-type reporter activity, which was set to 1. (D) HEK 293T cells
were cotransfected with empty vector or expression vectors for either p50 and p65, IRF-7, C/EBP, or c-Myc, together with either the BART P1 or P2 promoter
reporter, as indicated. Relative reporter activity was estimated and expressed as the fold change compared to the vector control. (E) HEK 293T cells were
transfected with either p50, p65, or p50 and p65 expression vectors together or with a control empty vector, together with the BART P1 or P2 promoter reporter.
Relative reporter activity was estimated and expressed as the fold change over that of the vector control. The expression of p50, p65, IB, and -tubulin was
confirmed by immunoblotting using specific antibodies. Relative luciferase activities are expressed as the fold change in luciferase activity, calculated by
normalizing firefly/Renilla ratios to those of the vector control. Experiments were performed in triplicate, and the results presented are the averages and standard
errors of the means from three independent experiments. P values were calculated using a two-tailed Student’s t test (*, P 0.05; **, P 0.01).
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FIG 2 NF-B binds to NF-B elements in the BART promoters. (A) Nucleotide sequences of the double-stranded probes and oligonucleotides used in the
competition experiments shown below. The NF-B binding sites in the BART P1 and P2 promoters, consisting of NF-B half-site sequence(s), are shown in bold
uppercase letters, and the mutated nucleotides are in red bold lowercase letters and underlined. (B and C) IRDye 700-labeled double-stranded synthetic
oligonucleotides corresponding to the BART P1 region from position73 to54 or the BART P2 region from position17 to2, as indicated, of the B95-8
sequence were incubated with nuclear extract from HEK 293T cells transfected with plasmids expressing EGFP-tagged p50 and Flag-tagged p65 and subjected to
EMSA. The black arrow indicates the NF-B/probe complex on the gel. Lanes 2 and 6 show the binding pattern of nuclear extract from untransfected cells, while
lanes 3 and 7 show the binding pattern of nuclear extract from p50/p65 transfected cells. Lanes 4 and 5 show the binding of the probe when an excess (300-fold)
of unlabeled wild-type or mutant competitor oligonucleotide was added to the binding reaction mixture. Supershift experiments with antibodies were performed
as indicated above the gels, with supershifted complexes indicated by an arrowhead in lanes 8 of panels B and C. (D) ChIP assay of NF-B p50 and p65 with the
BART promoter. HEK 293T cells were transfected with a plasmid containing the BART P1 promoter sequence and EGFP-tagged p50 and Flag-tagged p65. Results
of real-time PCR analysis and ChIP assays with antibodies specific for GFP or Flag or rabbit control IgG are shown. The results are expressed as fold enrichment,
where the value for the rabbit control IgG was set to 1. A genomic region	5 kb upstream of the IL-8 promoter was used as a negative control. The averages and
standard errors of the means from three independent experiments are shown, with all samples being analyzed in triplicate. P values were obtained from a
two-tailed Student’s t test (*, P 0.05; ***, P 0.001).
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BART lncRNAs with a pair of primers specific for the RPMS1
region found that BART RNA was upregulated almost 40-fold in
both the AGS-Bx1-LMP1 and HeLa-Bx1-LMP1 cell lines (Fig.
4E). Notably, additional expression of LMP1 in C666-1 cells did
not result in a similar level of upregulation of BART expression
(Fig. 4D and E). It is possible that C666-1 cells contain constitu-
tively active NF-B and that any additional effect resulting from
LMP1 expression, which is mediated by the same signaling path-
way, may be masked. These results further support the positive
effect of LMP1 on BART expression, presumably through NF-B
signaling, in EBV-infected epithelial cells.
EBV-harboring C666-1 NPC cells contain constitutively ac-
tivated NF-B and express higher levels of BARTs than other
EBV-infected epithelial cell lines. Expression of EBV BART
miRNAs is reported to be deregulated in EBV-associated neopla-
sia (24). We previously found that EBV-harboring C666-1 NPC
cells consistently express higher levels of miRNAs than EBV-in-
fected NP-460-Tert-EBV cells (37). This suggests that specific cel-
lular conditions may facilitate the high-level expression of BART
noncoding RNAs and miRNAs in NPC cells. To examine this idea,
we further compared BART expression levels in EBV-harboring
C666-1 NPC, AGS-Bx1, and HeLa-Bx1 cells. NF-B signaling is
constitutively activated in NPC cells (28, 29). We found that
C666-1 cells, but not AGS-Bx1 or HeLa-Bx1 cells, contained
nuclear p50 and p65 (Fig. 5A). While HeLa-Bx1 cells contained
lower copy numbers of the EBV genome, C666-1 and AGS-Bx1
cells harbored similar EBV copy numbers (Fig. 5B). We found
that C666-1 cells consistently expressed higher levels of BART
lncRNAs and miRNAs than either AGS-Bx1 or HeLa-Bx1 cells
(Fig. 5C and D). Interestingly, higher levels of Bcl-3, which is
upregulated by NF-B signaling, were also observed in C666-1
cells (Fig. 5A). We have shown above that NF-B signaling is
important for BART promoter activity. While it is suggested
that Bcl-3 may interact with NF-B, it remains to be evaluated
FIG 3 LMP1 expression activates BART P1 and P2 reporters through NF-B signaling. (A) Illustration of wild-type LMP1 and the mutated LMP1 showing
amino acid changes in CTAR2 from YYD to ID, resulting in reduced NF-B activation by LMP1, as described in a previous study (38). (B) HEK 293T cells were
transfected with an NF-B-responsive reporter, together with an empty vector or an LMP1 (wild-type or mutant) expression vector, and reporter activities were
determined 24 h after transfection. The expression of LMP1 and -tubulin was detected by immunoblotting using specific antibodies. (C and D) HEK 293T and
CNE2 cells were transfected with an empty vector or an LMP1 (wild-type or mutant) expression vector, with or without an IB-AA expression vector, together
with the BART P2 or P1 promoter reporter. Luciferase activities are expressed as the fold change in luciferase activity, calculated by normalizing firefly/Renilla
ratios to those of the vector control. Experiments were performed in triplicate, and the results are the averages and standard errors of the means from at least three
independent experiments. P values were calculated by two-tailed Student’s t test (*, P 0.05; **, P 0.01; ****, P 0.0001).
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if it is associated with the elevated levels of BART observed
in NPC cells. These data further strengthen the argument
that NF-B signaling contributes to BART expression in NPC
cells.
Inhibition ofNF-B signaling inC666-1 cells downregulates
BARTexpression.To further confirm the idea that NF-B activity
is critical for BART expression, we tested if inhibition of NF-B ac-
tivity would affect levels of BART in NPC cells. Acetylsalicylic acid
FIG 4 Stable expression of LMP1 in EBV-infected epithelial cell lines upregulates BART expression. (A) LMP1 protein expression from the AGS-Bx1-LMP1,
HeLa-Bx1-LMP1, and C666-1-LMP1 stable cell lines was examined by immunoblotting to demonstrate the overexpression of LMP1. (B to D) Levels of BART
miRNA expression in control and LMP1-expressing stable cell lines were determined by real-time PCR. BART miRNA expression was normalized to that of a host
miRNA, miR-Hsa-16, and is presented as fold change, with the expression levels of the control cell line being set to 1. (E) Levels of BART RPMS1 RNA expression
in control and LMP1-expressing stable cell lines were determined by real-time PCR using primers described in Table 1. RPMS1 RNA expression was normalized
to that of GAPDH and is presented as fold change, where the expression of the negative-control cell line was set to 1. Real-time PCR experiments were performed
in triplicate, and the results are the averages and standard errors of the means from at least three independent experiments. P values were calculated using a
two-tailed Student’s t test (*, P 0.05; ****, P 0.0001).
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FIG 5 NF-B activation and BART RNA and miRNA expression in EBV-infected epithelial cell lines. (A) Immunoblot analysis of nuclear and cytoplasmic
fractions from the cell lines C666-1, HeLa-Bx1, and AGS-Bx1, using specific antibodies. Antibodies against lamin AC were used to verify preparation of nuclear
and cytoplasmic fractions. (B) EBV copy numbers in the cell lines C666-1, HeLa-Bx1, and AGS-Bx1 were determined by amplifying a fragment of the BamH-W
region using qPCR. (C) Relative levels of BART miRNA in the EBV-infected epithelial cell lines C666-1, HeLa-Bx1, and AGS-Bx1 were determined by real-time
PCR. BART miRNA expression was normalized to that of miR-Hsa-16. (D) Relative levels of the alternatively spliced BART RNAs BARF0, RPMS1, RPMS1A, and
A73 in the EBV-infected epithelial cell lines C666-1, HeLa-Bx1, and AGS-Bx1 were determined by real-time PCR. BART RNA expression was normalized to that
of GAPDH. Real-time PCR experiments were performed in triplicate, and the results are the averages and standard errors of the means from three independent
RNA extractions. P values were calculated using a two-tailed Student’s t test (*, P 0.05; ns, not significant).
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(ASA; aspirin) is an anti-inflammatory drug which inhibits cycloox-
ygenase and IB (39–41), which is associated with NF-B signaling
(Fig. 6A). A previous study also reported that the IB kinase (IKK)
inhibitor PS-1145 specifically blocks TNF--induced NF-B activa-
tion through inhibition of IB phosphorylation and degradation
(42). When C666-1 cells were treated with either ASA or PS-1145,
immunoblot analysis showed a decrease in phosphorylated IB, in-
dicating reduced NF-B activation (Fig. 6B). Consistent with the de-
crease in NF-B activity, ASA and PS-1145 treatment significantly
downregulated the expression of all tested spliced forms of BART
lncRNAs, including BARF0, RPMS1, RPMS1A, and A73 (Fig. 6C).
Furthermore, examination of BART miRNA expression re-
FIG 6 Inhibition of NF-B signaling using acetylsalicylic acid (ASA) and the IB kinase inhibitor PS-1145 downregulates BART expression in C666-1 cells. (A)
Schematic showing the process of inhibition of NF-B signaling by ASA and PS-1145. (B) Immunoblot analysis of levels of phosphorylated IB protein from
C666-1 cells treated with either an ethanol (for ASA) or dimethyl sulfoxide (for PS-1145) control (CTL), 4 mM ASA, or 0.2 mM PS-1145 for 48 h. The protein
levels were quantified using Image Studio Lite software (Li-Cor) and normalized against the solvent control treatment. (C) Levels of BART lncRNAs from spliced
forms of BARF0, RPMS1, RPMS1A, and A73 RNA in C666-1 cells after treatment with either ASA, PS-1145, or solvent control for 48 h were determined by
real-time PCR. BART RNA expression was normalized to that of GAPDH and is presented as fold change, where the value for the solvent control was set to 1. (D)
Expression of BART miRNA in C666-1 cells after treatment with either ASA or solvent for 48 h was determined by real-time PCR. BART miRNA expression was
normalized to that of miR-Hsa-16 and is presented as fold change, with the value for the ethanol control set to 1. Real-time PCR experiments were performed in
triplicate, and the results are the averages and standard errors of the means from three independent experiments. P values were calculated from a two-tailed
Student’s t test comparison of results from NF-B inhibitor treatment to those with control treatment (*, P 0.05; ***, P 0.001; ****, P 0.0001).
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vealed lower levels of most BART miRNAs in ASA-treated
C666-1 cells (Fig. 6D). These results demonstrate that interfer-
ence with NF-B signaling causes downregulation of EBV
BART expression, further confirming that BART expression is
regulated by NF-B signaling.
BART miRNA targets the LMP1 3= UTR to downregulate
LMP1 protein expression. Expression of LMP1 in NPC cells is reg-
ulated by host mechanisms (30, 43). Because cells expressing LMP1
may be targeted by immune surveillance, it is believed that expression
of LMP1 is tightly regulated. Previous studies showed that EBV BART
miRNA could downregulate LMP1 expression (34, 35). It seems pos-
sible that LMP1 and BARTs form an autoregulatory loop in main-
taining EBV latency in NPC. To confirm whether BART miRNA may
serve as a negative regulator to modulate LMP1 protein expression,
we analyzed the targeting and downregulation of LMP1 by miR-
BART5-5p, which has an imperfect sequence match to the LMP1 3=
UTR (Fig. 7A). Reporters containing the entire LMP1 3= UTR fol-
lowed by the poly(A) signal or controls were used in coexpression
experiments with EBV-miR-BART5-5p (Fig. 7B). EBV-miR-
BART5-5p significantly downregulated luciferase activity for the re-
porter containing the LMP1 3= UTR, unlike miR-BART13-3p, which
has no sequence matches to the LMP1 3= UTR region and showed no
downregulation effect (Fig. 7B). Interestingly, a truncated form of the
LMP1 3= UTR which lacks the reported EBV-miR-BART5-5p target-
ing site was also downregulated by EBV-miR-BART5-5p, albeit less
strongly, suggesting that there may be multiple BART miRNA-tar-
geting sites within the LMP1 3= UTR
(Fig. 7C). Similarly, immunoblot analysis of HEK 293T cells stably
expressing LMP1 containing the 3= UTR showed downregulation of
LMP1 protein expression by miR-BART5-5p and, to a lesser extent,
by miR-BART3-3p and miR-BART7-3p but not by miR-BART13-3p
or miR-BART14-3p (Fig. 7D). These results confirm the ability of
BART miRNA to downregulate LMP1 and thereby form a negative
feedback loop to modulate expression of LMP1 in EBV-infected NPC
cells.
DISCUSSION
Epstein-Barr virus ubiquitously expresses a family of BamHI-A
rightward transcripts (BARTs), which are composed of alterna-
tively spliced forms of lncRNAs and two clusters of miRNAs de-
rived from the BamHI-A region of the viral genome, in all forms of
latency (12–14). Functions associated with BART miRNAs and
lncRNAs are being revealed, and expression of BART miRNA is
known to be deregulated in EBV-associated tumors (20, 22, 23, 24,
44). It is therefore necessary to understand how the expression of
BARTs is regulated in EBV-infected cells, in particular, in the set-
ting of EBV-associated tumors. We previously determined that
BARTs are expressed from two promoters and can be positively
regulated by C/EBP and c-Myc (25). This study further demon-
strated that NF-B signaling plays a crucial role in activation of
expression of BARTs. Activation of NF-B signaling by expression
of LMP1 or interference with NF-B signaling using chemicals
that inhibit phosphorylation of IB resulted in positive and neg-
ative modulation of BART expression, respectively. We propose
that EBV may utilize an autoregulatory loop to maintain expres-
sion of BARTs through constitutively activated NF-B signaling
while keeping LMP1-mediated NF-B signaling in check through
BART miRNA modulation in infected cells.
The most distinctive feature of EBV latency in NPC is the ex-
pression of high levels of BARTs, which include BART lncRNAs
and miRNAs, but few other latent products. It is reasonable to
postulate that the host mechanism which regulates the expression
of BARTs might be associated with the oncogenic state in NPC.
Based on our previous work identifying two promoters for the
expression of BARTs (25), this study set out to characterize the
aberrant signals which contribute to the expression of BARTs in
NPC. BARTs are expressed from two TATA-less promoters (P1
and P2). The BART P1 promoter contains a C/EBP motif, and
C/EBP was found to exert a positive effect on BART expression
(25). Since C/EBP is commonly expressed in epithelial cells, it
seems likely that other signaling pathways associated with the ma-
lignant status of cancer cells may contribute to the deregulation of
expression of BARTs in NPC. In this study, we identified several
potential NF-B sites between positions3 (P2) and69 (P1) in
the BART promoters and demonstrated binding of NF-B p50 to
the BART promoters. While the BART promoters contain only
half of the NF-B p50 consensus sequence, these sites seem suffi-
cient for NF-B p50 binding and mediation of NF-B signaling to
activate promoter activity. The fact that both NF-B sites in BART
P1 and P2 are p50 consensus half-sites may explain why the ChIP
assay is more efficient with p50 than with p65 and why only a
supershift with the p50 antibody was observed in EMSAs. Never-
theless, coexpression of p50 and p65 resulted in significant activa-
tion of BART promoter activity, suggesting that the p50/p65 het-
erodimer is important for BART promoter regulation. While
C/EBP and c-Myc were found to positively regulate BART expres-
sion, we showed that NF-B signaling has a more potent effect and
may be the dominant regulator for both BART promoters. It is still
unclear if P1 and P2 may be responsible for expression of different
species of BART lncRNAs or miRNAs.
Constitutively activated NF-B is implicated in the initiation and
progression of human cancers through its role in regulating cell pro-
liferation, apoptosis, cell transformation, and immunosuppression
(45, 46). In nasopharyngeal cells, infection with EBV can activate the
NF-B pathway, which likely contributes to tumor progression (47,
48). Interestingly, gene alterations or mutations in components in-
volved in NF-B pathways have been observed in NPC tumor lines
and primary tumor tissues (29). High levels of NF-B have been
demonstrated to inhibit gammaherpesvirus lytic replication in both
lymphoid and epithelial cells, while virus reactivation in NPC could
be achieved by inhibiting NF-B (49, 50). It seems possible that pre-
disposing genetic conditions may permit constitutively activated
NF-B signals in precancerous cells that facilitate EBV latency and
that expression of LMP1 following virus infection may further en-
hance aberrant NF-B signals, leading to NPC malignancy. Besides
being able to activate NF-B, LMP1 expression was also found to be
upregulated by NF-B, resulting in a positive regulatory loop be-
tween LMP1 expression and NF-B signaling (33). We previously
determined that aberrant STAT activity also contributes to the ex-
pression of LMP1 and Qp-EBNA1 in NPC cells (30, 43). These find-
ings point to a mechanism in which the combined effects of genetic
alteration and EBV infection may jointly trigger the onset or progres-
sion of NPC. While shedding of lytic replicating EBV is regularly
detected in saliva from positive carriers, EBV remains in a stringent
latent state in NPC cells. It may be speculated that predisposing con-
ditions, such as constitutively activated STAT3 and NF-B, in some
“precancerous” NP cells may facilitate EBV latency through expres-
sion of EBV EBNA1, LMP1, and high levels of BART miRNAs and
lncRNAs. EBV-encoded BART miRNAs have been shown to target
LMP1 and may prevent accumulation of overly high levels of LMP1
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that would otherwise lead to apoptosis or induce an immune re-
sponse (34, 35). Here, we further confirmed the linkage between
LMP1 and NF-B by showing that expression of BARTs is upregu-
lated by NF-B, that LMP1 positively regulates BART miRNA ex-
pression through NF-B signaling, and that expression of BART
miRNAs can downregulate LMP1 expression to provide negative
feedback. Maintaining high levels of BART miRNAs and lncRNAs in
cancer cells could have complex functions in cancer promotion, cell
survival, and immune evasion (Fig. 8).
In addition to the upregulation of BART miRNAs, we also
found that NF-B signaling regulated the alternatively spliced
BART lncRNAs, which was to be expected since BART miRNA
levels have been linked to the transcription of BART RNAs (17).
The exact function of BART lncRNAs remains to be elucidated since
FIG 7 EBV-encoded miR-BART5-5p modulates LMP1 expression. (A) The pmirGLO reporter plasmid constructs used to assess the effect of miR-BART5-5p on
the LMP1 3= UTR. (B) HEK 293T cells were transfected with pmirGLO-LMP1 or empty pmirGLO reporter, together with 50 nM total synthetic miRNA
(miR-control), miR-BART5-5p, or miR-BART13-3p duplexes. Reporter activity was determined 24 h after transfection. Firefly/Renilla ratios were normalized
against the same reporter transfected with the negative-control miRNA, and results are expressed as fold change in luciferase activity. (C) Sequence alignment of
miR-BART5-5p and the predicted binding site on the LMP1 3= UTR (35). HEK 293T cells were cotransfected with a pmirGLO-LMP1 or pmirGLO-truncated
LMP1 3= UTR reporter and either 50 nM miR-CTL or miR-BART5-5p. Firefly/Renilla ratios were normalized to levels of the same reporter transfected with
miR-CTL and expressed as fold change in luciferase activity. The results are the averages and standard errors of the means from three independent experiments.
P values are from a two-tailed Student’s t test comparison of results with the BART miRNA to those with the control miRNA (*, P 0.05; **, P 0.01; ***, P
0.001; ns, not significant). (D) HEK 293T cells stably expressing LMP1, including its 3= UTR, were transfected with 50 nM synthetic miRNA (control),
miR-BART3-3p, miR-BART5-5p, miR-BART7-3p, miR-BART13-3p, or miR-BART14-3p duplexes. Expression of LMP1 was detected by immunoblotting using
specific antibodies, and the intensities of bands were determined using Image Studio Lite software. Levels of-tubulin were determined as a loading control. The
intensities of the bands were normalized to the level of the negative-control miRNA and are expressed as fold change in protein expression.
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no study has been able to detect endogenous protein expression from
the BART open reading frames in EBV-infected cells (19, 51–53). A
recent study reported that expression of BART lncRANs altered cel-
lular gene expression, suggesting a potential function as yet undefined
(20). This study provides evidence that reemphasizes the critical role
of NF-B in modulating EBV latency in NPC. The cyclooxygenase 2
inhibitor ASA has been reported to induce EBV lytic replication by
inhibiting NF-B activity, resulting in cytotoxicity which could be
amplified by ganciclovir (49). The IB kinase inhibitor PS-1145 was
shown to block TNF--induced NF-B activation in multiple my-
eloma cells through inhibition of IB phosphorylation and degra-
dation (42). By treating C666-1 cells with ASA or PS-1145, we were
able to inhibit NF-B activity, resulting in downregulation of BART
RNA expression. The fact that inhibition of NF-B signaling both
downregulates BART expression and induces lytic replication makes
the NF-B pathway a potential target for future studies exploring
novel options for the treatment of EBV-associated carcinomas.
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